349 related articles for article (PubMed ID: 17368668)
1. Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution.
Steuber H; Heine A; Klebe G
J Mol Biol; 2007 May; 368(3):618-38. PubMed ID: 17368668
[TBL] [Abstract][Full Text] [Related]
2. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.
Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G
J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231
[TBL] [Abstract][Full Text] [Related]
3. Tracing changes in protonation: a prerequisite to factorize thermodynamic data of inhibitor binding to aldose reductase.
Steuber H; Czodrowski P; Sotriffer CA; Klebe G
J Mol Biol; 2007 Nov; 373(5):1305-20. PubMed ID: 17905306
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a novel binding site conformer of aldose reductase in ligand-bound state.
Steuber H; Zentgraf M; La Motta C; Sartini S; Heine A; Klebe G
J Mol Biol; 2007 May; 369(1):186-97. PubMed ID: 17418233
[TBL] [Abstract][Full Text] [Related]
5. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
[TBL] [Abstract][Full Text] [Related]
6. Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features.
Steuber H; Heine A; Podjarny A; Klebe G
J Mol Biol; 2008 Jun; 379(5):991-1016. PubMed ID: 18495158
[TBL] [Abstract][Full Text] [Related]
7. Tracing the detail: how mutations affect binding modes and thermodynamic signatures of closely related aldose reductase inhibitors.
Koch C; Heine A; Klebe G
J Mol Biol; 2011 Mar; 406(5):700-12. PubMed ID: 21185307
[TBL] [Abstract][Full Text] [Related]
8. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
9. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.
El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A
Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479
[TBL] [Abstract][Full Text] [Related]
10. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
11. The crystallographic structure of the aldose reductase-IDD552 complex shows direct proton donation from tyrosine 48.
Ruiz F; Hazemann I; Mitschler A; Joachimiak A; Schneider T; Karplus M; Podjarny A
Acta Crystallogr D Biol Crystallogr; 2004 Aug; 60(Pt 8):1347-54. PubMed ID: 15272156
[TBL] [Abstract][Full Text] [Related]
12. Virtual screening for inhibitors of human aldose reductase.
Kraemer O; Hazemann I; Podjarny AD; Klebe G
Proteins; 2004 Jun; 55(4):814-23. PubMed ID: 15146480
[TBL] [Abstract][Full Text] [Related]
13. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
Sotriffer CA; Krämer O; Klebe G
Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486
[TBL] [Abstract][Full Text] [Related]
14. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A
Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717
[TBL] [Abstract][Full Text] [Related]
15. Structure-based optimization of aldose reductase inhibitors originating from virtual screening.
Eisenmann M; Steuber H; Zentgraf M; Altenkämper M; Ortmann R; Perruchon J; Klebe G; Schlitzer M
ChemMedChem; 2009 May; 4(5):809-19. PubMed ID: 19301313
[TBL] [Abstract][Full Text] [Related]
16. Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex.
Petrova T; Steuber H; Hazemann I; Cousido-Siah A; Mitschler A; Chung R; Oka M; Klebe G; El-Kabbani O; Joachimiak A; Podjarny A
J Med Chem; 2005 Sep; 48(18):5659-65. PubMed ID: 16134934
[TBL] [Abstract][Full Text] [Related]
17. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
El-Kabbani O; Carbone V; Darmanin C; Oka M; Mitschler A; Podjarny A; Schulze-Briese C; Chung RP
J Med Chem; 2005 Aug; 48(17):5536-42. PubMed ID: 16107153
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of aldose reductase inhibition and docking studies of 6'-nitro and 6',6''-dinitrorosmarinic acids.
Koukoulitsa C; Bailly F; Pegklidou K; Demopoulos VJ; Cotelle P
Eur J Med Chem; 2010 Apr; 45(4):1663-6. PubMed ID: 20071057
[TBL] [Abstract][Full Text] [Related]
19. Kinetics and molecular docking studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors.
Jung HA; Moon HE; Oh SH; Kim BW; Sohn HS; Choi JS
Chem Biol Interact; 2012 May; 197(2-3):110-8. PubMed ID: 22543015
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of calf spleen purine nucleoside phosphorylase with two full trimers in the asymmetric unit: important implications for the mechanism of catalysis.
Bzowska A; Koellner G; Wielgus-Kutrowska B; Stroh A; Raszewski G; Holý A; Steiner T; Frank J
J Mol Biol; 2004 Sep; 342(3):1015-32. PubMed ID: 15342253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
